MedPAC Takes Anti-POD Stance in Report to Congress, Echoing an Increasingly Uniform Consensus

by Ropes & Gray LLP

Ropes & Gray LLP

On June 15, 2017, the Medicare Payment Advisory Commission (MedPAC), a non-partisan group that advises Congress on Medicare policy, released its annual Report to the Congress on Medicare and the Health Care Delivery System (the “Report”). Of particular importance to some hospitals and physicians, the Report includes MedPAC’s first-ever discussion of physician-owned distributorships of implantable medical devices (PODs), and specifically calls for actions to “reduce the number” of PODs. Echoing the findings of prior governmental investigations, the Report also notes that PODs can lead and have led to increased costs and inappropriate care.

MedPAC’s commentary follows on the heels of a 2016 report critical of PODs from the majority staff of the Senate Finance Committee (SFC), which, as we discussed in a recent article in Compliance Today, concluded among other things that PODs are “harmful to patients and payers.” The Report builds on an ever-increasing consensus of policymakers, regulators, law enforcement, consumer groups, health care providers, and other stakeholders—including the SFC, the Office of Inspector General of the U.S. Department of Health and Human Services (OIG), the Centers for Medicare & Medicaid Services (CMS), the U.S. Department of Justice (DOJ), the Association for Medical Ethics, and the Advanced Medical Technology Association (AdvaMed)—that the conflict of interest inherent in the POD business model should be eliminated.

MedPAC’s Report includes a discussion of issues that critics have sounded regarding PODs, including that they may lead to increased volume of surgery, increased intensity of procedures, inappropriate care, and higher device costs. It also provides considerations for potential policy changes:

  1. Improve Open Payments Reporting and Monitoring. MedPAC observed that few PODs report through the Sunshine Act Open Payments reporting system—it indicated that it was able to identify a total of only 22 PODs in 2015 reporting data. In part, that low volume may be due to the fact that under the current regulatory interpretation of the Sunshine law, PODs that do not manufacture the implants ordered by their physician-owners are deemed exempt from reporting if they sell to only one hospital (and thus do not meet the regulatory definition of “Group Purchasing Organization” required to disclose payments to physicians). MedPAC also suggested that the low number may be due in part to PODs having changed how they compensate physicians “to circumvent reporting requirements.” Additionally, MedPAC indicated that the low volume of disclosures could be partially due to the fact that current Open Payments data are not transparent regarding the type of reporting entity, making it difficult to identify PODs definitively. Based on its findings, MedPAC suggested policy changes that would do the following:
    • Require all PODs to report under the Open Payments program.
    • Require each disclosing entity to indicate whether it is a POD, and what type of products it makes or distributes.
    • Require CMS to coordinate with OIG and to remind PODs or suspected PODs of their reporting obligations, and to impose penalties for non-compliance.
  2. Reduce Prevalence of PODs. MedPAC’s Report went further than merely suggesting increased transparency, commenting that actions also should be taken “to reduce the number of PODs.” It suggested that such measures could include revisions to physician self-referral regulations, presumably a reference to changes that could be made to the regulations implementing the Stark Law (or the Anti-Kickback Statute). Another measure to reduce the number of PODs could be to require that hospitals adopt policies that curtail purchases from PODs. This consideration is not included in the Report, but is one that was suggested by MedPAC staff to the commissioners in April, and echoes similar recommendations made in 2016 in the SFC report.

The MedPAC commentary adds the voice of Congress’s chief advisor on Medicare payment issues to a decade-long trend ringing increasingly loud alarm bells about PODs:

  • 2008: CMS expresses concern that PODs may “serve little purpose other than providing physicians the opportunity to earn economic benefits in exchange for nothing more than ordering medical devices or other products that the physician-investors use on their own patients.”
  • 2011: SFC (then) minority staff releases its first report questioning the propriety of PODs, observing “[t]he very nature of PODs seem to create financial incentives for physician investors to use those devices that give them the greatest financial return and that, in the process, patient treatment decisions may be based on personal financial gain.”
  • 2013: OIG issues its Special Fraud Alert (SFA) enumerating elements exhibited by PODs that make them “inherently suspect” under the Anti-Kickback Statute, including features common in the POD business model, such as:
    1. the POD offers investment interests primarily or exclusively to physicians who are expected to order or recommend implants sold by the POD;
    2. the POD primarily or exclusively serves its physician-owners’ patient base;
    3. physician-owners shift to the POD’s products on a primary or exclusive basis after joining a POD;
    4. physician-owners condition their referrals to hospitals by coercion (such as threats that they will go elsewhere unless the hospital buys implants sold by the POD); and
    5. physician-owners are few enough in number that the volume or value of a physician’s own referrals correlates closely to investment return.
  • 2013: OIG also publishes the results of its research into actual hospital purchases from PODs, concluding that PODs result in increased utilization of implantable devices compared to procedures performed with implants not acquired by PODs, and yield no cost savings (and in some cases increase costs).
  • 2014: DOJ files a civil case against Reliance Medical Systems LLC (Reliance), two of Reliance’s affiliated PODs, and some of their investors for violations of the Anti-Kickback Statute and the False Claims Act. The Complaint is based on the legal theory that physician-owner return on investment in Reliance PODs constitutes a kickback to induce the physicians to order Reliance implants for their own patient procedures, resulting in the submission of false claims to Medicare.
  • 2016: SFC majority staff releases its second report on PODs, relying on evidence collected from its investigations, and stating in stronger terms that the committee is “highly concerned about the damage that PODs have done, and are continuing to do, to patient safety and federal healthcare programs.”
  • 2017: A physician involved in the Reliance case is sentenced to 19 years, seven months in prison for $2.8 million in criminal healthcare fraud. The physician admitted to persuading a hospital where he performed procedures to buy the implants that he ordered for those procedures from a Reliance POD, Apex Medical Technologies, in which he had ownership stake. Additionally, the physician conceded that economic benefits of the POD motived him to perform medically unnecessary surgeries.

Despite its forceful denunciation of the POD business model, it is unlikely that the Report will lead to any immediate actions by Congress or Medicare regulators. Congress’s attention to health care currently is focused on the “repeal and replace” of Obamacare (which we discuss here), and CMS is similarly involved with considering whether and how to move forward with several Obama Administration initiatives, such as value-based health care (which we discuss here). However, it is significant that another independent inquiry, this one by Congress’s chief non-partisan advisor on Medicare policy, has concluded that physician self-referral to PODs ought to be curtailed. The Report will add another arrow to the quiver of False Claims Act qui tam relators and law enforcement as they challenge POD relationships. Moreover, in the aftermath of the OIG’s 2013 SFA and subsequent report, many hospitals adopted policies forbidding or severely restricting dealing with PODs that exhibit any of the SFA’s suspect characteristics. Together with the SFC’s 2016 report, MedPAC’s commentary will make it that much harder for hospitals and physicians to initiate or maintain relationships with PODs.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Ropes & Gray LLP | Attorney Advertising

Written by:

Ropes & Gray LLP

Ropes & Gray LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.